Pair Name	All-trans retinoic acid, Decitabine
Phytochemical	All-trans-retinoic acid
Drug	Decitabine
Disease Info	[ICD-11: 2A60.Z]	Acute myeloid leukemia		Investigative
Regulate Info	Down-regulation	NAD(P)H dehydrogenase [quinone] 1		Expression
Result	These results demonstrate that combining DAC and ATRA has potential for the clinical treatment of HR-MDS/AML and merits further exploration.

Pair Name	Bruceine D, Gemcitabine
Phytochemical	Bruceine D
Drug	Gemcitabine
Disease Info	[ICD-11: 2C10.0]	Pancreatic ductal adenocarcinoma		Investigative
Regulate Info	Down-regulation	NAD(P)H dehydrogenase [quinone] 1		Expression
Result	Our experimental findings indicate that BD, a potent Nrf2 inhibitor, holds promise for further development into a novel adjuvant therapy for PDAC.

Pair Name	Dehydrobruceine B, Cisplatin
Phytochemical	Dehydrobruceine B
Drug	Cisplatin
Disease Info	[ICD-11: 2C25]	Lung cancer		Investigative
Regulate Info	Down-regulation	NAD(P)H dehydrogenase [quinone] 1		Expression
Result	These results generated a rationale for further investigation of DHB combined with CDDP as a potential therapeutic strategy in lung cancer.

Pair Name	Glucosinalbate, Doxorubicin
Phytochemical	Glucosinalbate
Drug	Doxorubicin
Disease Info	[ICD-11: 2C90]	Ehrlich ascites carcinoma		Investigative
Regulate Info	Up-regulation	NAD(P)H dehydrogenase [quinone] 1		Expression
Result	The present study clearly suggested therapeutic benefit of I3C in combination with DOX by augmenting anticancer efficacy and diminishing toxicity to the host.

Pair Name	Hederagenin, Cisplatin
Phytochemical	Hederagenin
Drug	Cisplatin
Disease Info	Head and neck cancer
Regulate Info	Down-regulation	NAD(P)H dehydrogenase [quinone] 1		Expression
Result	Hederagenin effectively targets cisplatin-resistant HNC cells in vitro and in vivo. Consistent with its effects in other types of cancer, hederagenin markedly induces apoptosis in HNC cells by activating the mitochondria-driven intrinsic apoptotic pathway. We demonstrated that the apoptosis-inducing effects of hederagenin are mediated by the inhibition of the Nrf2-ARE antioxidant pathway.

Pair Name	Luteolin, Lapatinib
Phytochemical	Luteolin
Drug	Lapatinib
Disease Info	[ICD-11: 2C60]	Breast cancer		Investigative
Regulate Info	Up-regulation	NAD(P)H dehydrogenase [quinone] 1		Expression
Result	These data suggest that the combination of Lapatinib and luteolin may inhibit HER2 human breast cancer by significantly increasing the expression of FOXO3a and NQO1, two key genes in HER2 human breast cancer xenografts.

Pair Name	Polydatin, Brusatol
Phytochemical	Polydatin
Drug	Brusatol
Disease Info	[ICD-11: 2C60]	Breast cancer		Investigative
Regulate Info	Down-regulation	NAD(P)H dehydrogenase [quinone] 1		Expression
Result	We could significantly reduce tumor cell growth while avoiding toxic side effects, providing a treatment method with greater clinical application value for TNBC treatment.

Pair Name	Trigonelline, Cisplatin
Phytochemical	Trigonelline
Drug	Cisplatin
Disease Info	[ICD-11: 2C25]	Lung cancer		Investigative
Regulate Info	Down-regulation	NAD(P)H dehydrogenase [quinone] 1		Expression
Result	Our study demonstrated that Trigonelline blocks Nrf2 activation and its nuclear translocation via inhibition of EGFR signalling pathway. It has improved responsiveness of NSCLC cells for Cisplatin and Etoposide and could be a promising choice for lung cancer therapy. Toxicol In Vitro. 2021 Feb;70:105038. doi: 10.1016/j.tiv.2020.105038.

Pair Name	Wogonin, Cisplatin
Phytochemical	Wogonin
Drug	Cisplatin
Disease Info	Head and neck cancer
Regulate Info	Down-regulation	NAD(P)H dehydrogenase [quinone] 1		Expression
Result	Wogonin induced selective cell death by targeting the antioxidant defense mechanisms enhanced in the resistant HNC cells and activating cell death pathways involving PUMA and PARP. Hence, wogonin significantly sensitized resistant HNC cells to cisplatin both in vitro and in vivo. Wogonin is a promising anticancer candidate that induces ROS accumulation and selective cytotoxicity in HNC cells and can help to overcome cisplatin-resistance in this cancer.

Pair Name	Brusatol, Gemcitabine
Phytochemical	Brusatol
Drug	Gemcitabine
Disease Info	[ICD-11: 2C10]	Pancreatic cancer		Investigative
Regulate Info	Down-regulation	NAD(P)H dehydrogenase [quinone] 1		Expression
Result	Our results suggest that brusatol is capable of enhancing the antitumour effects of gemcitabine in both pancreatic cancer cells and PANC-1 xenografts via suppressing the Nrf2 pathway.

Pair Name	Luteolin, Oxaliplatin
Phytochemical	Luteolin
Drug	Oxaliplatin
Disease Info	[ICD-11: 2B90]	Colon cancer		Investigative
Regulate Info	Down-regulation	NAD(P)H dehydrogenase [quinone] 1		Expression
Result	Adaptive activation of Nrf2 may contribute to the development of acquired drug-resistance and luteolin could restore sensitivity of oxaliplatin-resistant cell lines to chemotherapeutic drugs. Inhibition of the Nrf2 pathway may be the mechanism for this restored therapeutic response.

Pair Name	Ursolic acid, Cisplatin
Phytochemical	Ursolic acid
Drug	Cisplatin
Disease Info	[ICD-11: 2C12]	Hepatocellular carcinoma		Investigative
Regulate Info	Down-regulation	NAD(P)H dehydrogenase [quinone] 1		Expression
Result	The results confirmed the sensibilization of UA on HepG2/DDP cells to cisplatin, which was possibly mediated via the Nrf2/antioxidant response element pathway.

Pair Name	Ursolic acid, Cisplatin
Phytochemical	Ursolic acid
Drug	Cisplatin
Disease Info	[ICD-11: 2C12]	Hepatocellular carcinoma		Investigative
Regulate Info	Down-regulation	NAD(P)H dehydrogenase [quinone] 1		Expression
Result	Ursolic acid sensitizes cisplatin-resistant HepG2/DDP cells to cisplatin via inhibiting Nrf2/ARE pathway